CORONA Remedies Limited announced strong unaudited financial results for the third quarter and nine months ended December 31, 2025.
Consolidated revenue from operations reached Rs 342.42 crore for Q3 FY26, up 15 percent year-on-year, and Rs 1,050.09 crore for the nine months, reflecting 16.3 percent growth. Profit after tax, excluding a one-time statutory impact of Rs 14.29 crore from the New Labour Code, stood at Rs 55.56 crore for the quarter (16.2 percent margin) and at Rs 154.08 crore for nine months (14.7 percent margin). This marks YoY growth of 23.7 percent and 30.7 percent, respectively.
EBITDA hit Rs 83.16 crore in Q3 with a 24.3 percent margin, and Rs 231.42 crore for nine months at 22 percent. Key metrics for nine months include annualized RoE of 31.1 percent, RoCE of 48 percent, OCF to EBITDA at 86.3 percent, and net working capital days at 18.
Nirav K. Mehta, Managing Director and CEO, said, “We are delighted to report a strong financial performance in Q3 and 9MFY26. Revenues grew 15 percent and 16.3 percent, respectively, on a YoY basis, outperforming the IPM growth. Adjusted PAT rose 23.7 percent and 30.7 percent while maintaining healthy return ratios. We transformed our aspiration of 15 percent revenue and 20 percent PAT growth into achievement over the last three quarters and remain optimistic.”
He added that the results stem from a consistent strategy, disciplined execution, field force strengthening, brand portfolio expansion, and focus on specialists’ prescriptions, building a sustainable growth platform.
